| Identification | Back Directory | [Name]
BIBX 1382 DIHYDROCHLORIDE | [CAS]
196612-93-8 | [Synonyms]
CS-928
Falnid
Falnidamol
Unii-0mu316797d
Falnidamol [inn]
BIBX 1382 DIHYDROCHLORIDE
FALNIDAMOL; BIBX-1382; BIBX 1382
8-(3-Chloro-4-fluoroanilino)-2-((1-methyl-4-piperidyl)amino)pyrimido(5,4-D)pyrimidine
N4-(3-chloro-4-fluoro-phenyl)-N6-(1-methyl-4-piperidyl)pyrimido[5,4-d]pyrimidine-4,6-diamine
N8-(3-Chloro-4-fluorophenyl)-N2-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-2,8-diamine
N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine
Pyrimido(5,4-D)pyrimidine-2,8-diamine, N8-(3-chloro-4-fluorophenyl)-N2-(1-methyl-4-piperidinyl)-
N8-(3-Chloro-4-fluorophenyl)-N2-(1-methyl-4-piperidinyl)-pyrimido[5,4-d]pyrimidine-2,8-diaminedihydrochloride
N8-(3-CHLORO-4-FLUOROPHENYL)-N2-(1-METHYL-4-PIPERIDINYL)-PYRIMIDO[5,4-D]PYRIMIDINE-2,8-DIAMINE DIHYDROCHLORIDE
N8-(3-Chloro-4-fluorophenyl)-N2-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-2,8-diamine BIBX 1382
BIBX 1382 dihydrochloride,N8-(3-Chloro-4-fluorophenyl)-N2-(1-methyl-4-piperidinyl)-pyrimido[5,4-d]pyrimidine-2,8-diaminedihydrochloride | [Molecular Formula]
C18H19ClFN7 | [MDL Number]
MFCD08703119 | [MOL File]
196612-93-8.mol | [Molecular Weight]
387.84 |
| Chemical Properties | Back Directory | [Melting point ]
>217°C (dec.) | [Boiling point ]
552.0±60.0 °C(Predicted) | [density ]
1.427 | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
8?+-.0.10(Predicted) | [color ]
Pale Yellow to Yellow | [Water Solubility ]
water: 1mg/mL
DMSO: 25mg/mL | [InChI]
1S/C18H19ClFN7/c1-27-6-4-11(5-7-27)25-18-21-9-15-16(26-18)17(23-10-22-15)24-12-2-3-14(20)13(19)8-12/h2-3,8-11H,4-7H2,1H3,(H,21,25,26)(H,22,23,24) | [InChIKey]
FTFRZXFNZVCRSK-UHFFFAOYSA-N | [SMILES]
Fc1c(cc(cc1)Nc2ncnc3c2nc(nc3)NC4CCN(CC4)C)Cl |
| Hazard Information | Back Directory | [Uses]
BIBX 1382 Dihydrochloride, is a potent, selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 3 nM). | [Uses]
Falnidamol is a novel ErbB receptor kinase inhibitor that is more potent at inhibiting signaling induced by TGF-α than that induced by neuregulin1-β1 or anti-ErbB2 agonist antibodies. | [Definition]
ChEBI: N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine is a substituted aniline. | [Biological Activity]
Potent, selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC 50 = 3 nM). Displays > 1000-fold lower potency against ErbB2 (IC 50 = 3.4 μ M) and a range of other related tyrosine kinases (IC 50 > 10 μ M). Oral administration inhibits growth of established human xenografts in athymic mice. | [in vivo]
Falnidamol (BIBX 1382; p.o.; 10 mg/kg/day; 16 days) completely suppressed tumor growth of human A431 xenografts with respective a T/C value of 15% after 2 weeks of treatment[2].
Falnidamol (50 mg/kg/day for 2 weeks) results in dephosphorylation of the EGF receptor in A431 xenograft-bearing mice[2].
With Falnidamol (p.o.; 10 mg/kg/day; 16 days), the C4h is 2222 nM and the C24h is 244 nM[2].
| Animal Model: | Five- to six-week-old athymic NMRI-nu/nu female mice (21-31 g) with A431, FaDu, or HN5 cells[2] | | Dosage: | 10 mg/kg | | Administration: | p.o.; daily; 16 days | | Result: | Completely suppressed tumor growth of human A431 xenografts with respective T/C values of 15 and 6% after 2 weeks of treatment.
|
| Animal Model: | Five- to six-week-old athymic NMRI-nu/nu female mice (21–31 g) with A431 cells[2] | | Dosage: | 10 mg/kg (Pharmacokinetic Analysis) | | Administration: | p.o.; daily; 16 days | | Result: | The C4h is 2222 nM and the C24h is 244 nM.
|
| [IC 50]
EGFR: 3 nM (IC50); ErbB2: 3.4 μM (IC50) | [References]
1. f. f. solca, a. baum, e. langkopf, g. dahmann, k. h. heider, f. himmelsbach and j. c. van meel, j pharmacol exp ther 2004, 311, 502-509. |
|
|